Helius Medical Technologies, Inc. is a neurotechnology company. The Company is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
Unternehmens-codeHSDT
Name des UnternehmensHelius Medical Technologies Inc
IPO-datumJun 27, 2014
Gegründet am2018
CEOMr. Dane C. Andreeff
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJun 27
Addresse642 Newtown Yardley Road
StadtNEWTOWN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl18940
Telefon12159446100
Websitehttps://heliusmedical.com/
Unternehmens-codeHSDT
IPO-datumJun 27, 2014
Gegründet am2018
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten